Less EQ and YoE were associated with brain alterations across groups. 2 key findings →
Design: cross-sectional Participants: 7,533 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 2699 articles initially screened, 21 studies were included, encompassing over 1 million participants. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Older patients with a college education who present with complaints of cognitive decline (reported by themselves or others) and score less than 27 on the MMSE are at a greater risk of being diagnosed with dementia and should be referred for a comprehensive dementia evaluation, including formal neuropsychological testing. 2 key findings →
Participants: 307 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of comorbid conditions in people with dementia is high. 3 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Behavioral symptoms such as repetitive speech, wandering, and sleep disturbances are a core clinical feature of Alzheimer disease and related dementias. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Optimal ranges of CDR-SOB scores corresponding to the global CDR scores were 0.5 to 4.0 for a global score of 0.5, 4.5 to 9.0 for a global score of 1.0, 9.5 to 15.5 for a global score of 2.0, and 16.0 to 18.0 for a global score of 3.0. 2 key findings →
Participants: 1,577 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our model could aid GPs or health service planners with the early detection of dementia. 1 key finding →
Design: case-control study Participants: 93,120 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Beneficiaries included 2,713,573 White, 251,958 Black, 196,845 Hispanic, 95,719 Asian, 11,727 American Indian/Alaska Native, and 63,795 of other race/ethnicity. 5 key findings →
Design: retrospective cohort Participants: 3,333,617 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Care quality has important implications for people with dementia. 1 key finding →
Design: cohort study Participants: 373,695 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The overall PAF for the 14 modifiable risk factors was 59.5% (95% CI = 58.5-60.5). 5 key findings →
Design: longitudinal study Participants: 9,949 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During the 4-year follow-up, 134 individuals were diagnosed with dementia. 5 key findings →
Design: cohort study Participants: 2,220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PLWD also commonly experience social isolation (Shen et al., 2022), poorer physical function (Jehu et al., 2024a), worsened behavioral and psychological symptoms (Cerejeira et al., 2012), poorer quality of life (Cerejeira et al., 2012), and reduced access to healthcare (Mitchell et al., 2016) compared to older adults without dementia. 5 key findings →
Design: randomized controlled trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Despite mortality due to communicable diseases, poverty, and human conflicts, dementia incidence is destined to increase in the developing world in tandem with the ageing population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Quantitative imaging of cerebral blood flow and metabolism by positron emission tomography can differentiate between vascular dementia and degenerative dementia and show the interaction between vascular and metabolic changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In India, increasing lifespan and decreasing fertility rates have resulted in a growing number of older persons. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Survey-based cognitive tests and claims-based dementia diagnosis yielded equal prevalence estimates, yet only half were identified by both measures. 4 key findings →
Participants: 10,450 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Survival after dementia diagnosis differs by race/ethnicity, with shortest survival among whites and longest among Asian Americans. 3 key findings →
Participants: 23,032 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Two of every three persons living with dementia reside in low- and middle-income countries (LMICs). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Numerous tools for assessment of cognitive impairment in low-literacy settings have been developed, and tools developed for use in high-income countries have also been validated in low-literacy settings. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dementia is an increasing focus for policymakers, civil organizations and multidisciplinary researchers. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Declines in heart disease and stroke mortality rates are conventionally attributed to reductions in cigarette smoking, recognition and treatment of hypertension and diabetes, effective medications to improve serum lipid levels and to reduce clot formation, and general lifestyle improvements. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Progression of Alzheimer dementia (AD) is highly variable. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The final Dementia Screening Indicator included age (1 point/year; ages, 65-79 years), less than 12 years of education (9 points), stroke (6 points), diabetes mellitus (3 points), body mass index less than 18.5 kg/m(2) (8 points), requiring assistance with money or medications (10 points), and depressive symptoms (6 points). 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. 4 key findings →
Participants: 181 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
57/100
Current dementia risk scores have had limited success in consistently identifying at-risk individuals across different ages and geographical locations. 4 key findings →
Participants: 176 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events